What is JUPITER NEUROSCIENCES, INC.'s earnings per share (EPS)?

JUPITER NEUROSCIENCES, INC. (JUNS) reported diluted earnings per share of $-0.25 for fiscal year 2025. This represents a -212.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

JUPITER NEUROSCIENCES, INC. Financials

JUNS

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows JUPITER NEUROSCIENCES, INC. (JUNS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI JUNS FY2025 2026-05-14

External financing is carrying a near-pre-revenue business whose cost base is expanding faster than customer activity.

The latest year brought financing cash flow of $5.43M, yet year-end cash was still only $3.79M because operating burn absorbed most of the fresh capital. That pairing means fundraising is funding operations, not building a reserve, which helps explain why equity moved from positive in FY2024 to negative in FY2025 even though cash barely changed.

The 80.6% gross margin on just $21.8K of revenue does not describe a working commercial engine; it mainly shows that almost all of the cost structure sits below gross profit. SG&A of $6.84M and R&D of $2.09M show a company still being financed around development and corporate overhead rather than customer receipts.

The balance sheet briefly looked repaired in FY2024, but the latest year ended with negative equity of -$1.83M and a current ratio of 0.7x, so that repair did not stick. With current liabilities of $7.40M against current assets of $4.82M, most obligations appear concentrated in the near term rather than comfortably pushed out.

Financial Health Signals

Financial Profile 17/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of JUPITER NEUROSCIENCES, INC.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

JUPITER NEUROSCIENCES, INC. has an operating margin of -40873.2%, meaning the company retains $-40873 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.

Leverage

JUPITER NEUROSCIENCES, INC. carries a low D/E ratio of -4.04, meaning only $-4.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

JUPITER NEUROSCIENCES, INC.'s current ratio of 0.65 is below the typical benchmark, resulting in a score of 7/100. However, the company holds substantial cash reserves (51% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Piotroski F-Score Weak

2/9

JUPITER NEUROSCIENCES, INC. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.63x

For every $1 of reported earnings, JUPITER NEUROSCIENCES, INC. generates $0.63 in operating cash flow (-$5.4M OCF vs -$8.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-134.9x

JUPITER NEUROSCIENCES, INC. earns $-134.9 in operating income for every $1 of interest expense (-$8.9M vs $66K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$22K

JUPITER NEUROSCIENCES, INC. generated $22K in revenue in fiscal year 2025.

EBITDA

N/A

Net Income

-$8.6M

YoY-254.4%

JUPITER NEUROSCIENCES, INC. reported -$8.6M in net income in fiscal year 2025. This represents a decrease of 254.4% from the prior year.

EPS (Diluted)

$-0.25

YoY-212.5%

JUPITER NEUROSCIENCES, INC. earned $-0.25 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 212.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.8M

YoY+0.5%

JUPITER NEUROSCIENCES, INC. held $3.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

34M

YoY+4.1%

JUPITER NEUROSCIENCES, INC. had 34M shares outstanding in fiscal year 2025. This represents an increase of 4.1% from the prior year.

Margins & Returns

Gross Margin

80.6%

JUPITER NEUROSCIENCES, INC.'s gross margin was 80.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.

Operating Margin

-40873.2%

JUPITER NEUROSCIENCES, INC.'s operating margin was -40873.2% in fiscal year 2025, reflecting core business profitability.

Net Margin

-39662.8%

JUPITER NEUROSCIENCES, INC.'s net profit margin was -39662.8% in fiscal year 2025, showing the share of revenue converted to profit.

Return on Equity

N/A

Capital Allocation

R&D Spending

$2.1M

YoY+323.5%

JUPITER NEUROSCIENCES, INC. invested $2.1M in research and development in fiscal year 2025. This represents an increase of 323.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

JUNS Income Statement

Metric	FY25	FY24	FY23
Revenue	$22K	$0	N/A
Cost of Revenue	$4K	N/A	N/A
Gross Profit	$18K	N/A	N/A
R&D Expenses	$2.1M+323.5%	$493K	N/A
SG&A Expenses	$6.8M+163.2%	$2.6M	N/A
Operating Income	-$8.9M-188.2%	-$3.1M	N/A
Interest Expense	$66K-73.4%	$248K+13.6%	$219K
Income Tax	N/A	N/A	N/A
Net Income	-$8.6M-254.4%	-$2.4M	N/A
EPS (Diluted)	$-0.25-212.5%	$-0.08+55.6%	$-0.18

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$19K	N/A	N/A	N/A	$0	N/A	N/A	N/A
Cost of Revenue	$4K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$14K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$411K	N/A	$817K+7.5%	$759K+62.7%	$467K	N/A	$92K-9.1%	$101K
SG&A Expenses	$1.6M	N/A	$1.5M-1.7%	$1.5M+40.5%	$1.1M	N/A	$402K-11.9%	$456K
Operating Income	-$2.0M	N/A	-$2.3M-1.4%	-$2.3M-47.3%	-$1.5M	N/A	N/A	-$557K
Interest Expense	$119K	N/A	$1K+5.1%	$1K-7.6%	$1K	N/A	$107K+90.8%	$56K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.1M	N/A	-$2.3M-1.6%	-$2.3M-47.4%	-$1.5M	N/A	N/A	$313K
EPS (Diluted)	$-0.06	N/A	$-0.070.0%	$-0.07-40.0%	$-0.05	N/A	$-0.02-300.0%	$0.01

JUNS Balance Sheet

Metric	FY25	FY24	FY23
Total Assets	$5.6M-10.3%	$6.2M+4074.1%	$149K
Current Assets	$4.8M+3.8%	$4.7M+16081.0%	$29K
Cash & Equivalents	$3.8M+0.5%	$3.8M+13136.6%	$28K
Inventory	$160K	N/A	N/A
Accounts Receivable	$3K	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$7.4M+264.3%	$2.0M-65.9%	$5.9M
Current Liabilities	$7.4M+268.1%	$2.0M-65.2%	$5.8M
Long-Term Debt	N/A	N/A	N/A
Total Equity	-$1.8M-143.9%	$4.2M+171.9%	-$5.8M
Retained Earnings	-$34.7M-33.2%	-$26.0M-10.3%	-$23.6M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$3.9M-29.0%	$5.6M+116.0%	$2.6M-35.1%	$4.0M-20.0%	$5.0M-20.0%	$6.2M+7150.4%	$86K	N/A
Current Assets	$3.4M-29.3%	$4.8M+195.6%	$1.6M-42.1%	$2.8M-21.9%	$3.6M-22.3%	$4.7M+904620.4%	$514	N/A
Cash & Equivalents	$2.4M-37.6%	$3.8M+423.5%	$724K-61.5%	$1.9M-30.6%	$2.7M-28.2%	$3.8M+1489824.9%	$253	N/A
Inventory	$148K-7.3%	$160K	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	$3K	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.7M-9.0%	$7.4M+193.6%	$2.5M-4.2%	$2.6M+38.4%	$1.9M-6.5%	$2.0M-65.2%	$5.8M	N/A
Current Liabilities	$6.7M-9.0%	$7.4M+193.6%	$2.5M-4.2%	$2.6M+39.1%	$1.9M-5.9%	$2.0M-64.6%	$5.7M	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.8M-51.9%	-$1.8M-3290.4%	$57K-95.7%	$1.3M-56.3%	$3.1M-26.5%	$4.2M+172.5%	-$5.8M-7.4%	-$5.4M
Retained Earnings	-$36.7M-5.9%	-$34.7M-8.0%	-$32.1M-7.7%	-$29.8M-8.2%	-$27.6M-5.9%	-$26.0M-6.2%	-$24.5M	N/A

JUNS Cash Flow Statement

Metric	FY25	FY24	FY23
Operating Cash Flow	-$5.4M-38.4%	-$3.9M-713.2%	-$481K
Capital Expenditures	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A
Financing Cash Flow	$5.4M-29.0%	$7.7M+1619.6%	$445K
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.4M+39.5%	-$2.4M-105.1%	-$1.2M-39.4%	-$828K+22.1%	-$1.1M+71.2%	-$3.7M-8575.9%	-$43K+60.4%	-$107K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$6K	N/A	N/A	N/A	N/A	$7.5M+26560.8%	$28K-75.4%	$114K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

JUNS Financial Ratios

Metric	FY25	FY24	FY23
Gross Margin	80.6%	N/A	N/A
Operating Margin	-40873.2%	N/A	N/A
Net Margin	-39662.8%	N/A	N/A
Return on Equity	N/A	-58.5%	N/A
Return on Assets	-155.4%-116.0pp	-39.3%	N/A
Current Ratio	0.65-1.7	2.31+2.3	0.01
Debt-to-Equity	-4.04-4.5	0.49+1.5	-1.03
FCF Margin	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	76.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-10524.3%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-11054.9%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-3984.9%-3816.8pp	-168.1%-118.2pp	-49.9%	N/A	N/A	N/A
Return on Assets	-52.2%	N/A	-88.8%-32.0pp	-56.8%-26.0pp	-30.8%	N/A	N/A	N/A
Current Ratio	0.51-0.1	0.650.0	0.65-0.4	1.07-0.8	1.91-0.4	2.31+2.3	0.00	N/A
Debt-to-Equity	-2.42+1.6	-4.04-47.9	43.87+41.9	1.96+1.3	0.62+0.1	0.49+1.5	-1.01	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.65), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Bioxcel Therapeutics Inc BTAI

$30.6M

Vtv Therapeutics VTVT

$139.8M

Serina Therapeutics SER

$22.6M

Applied Therapeutics APLT

$14.9M

MAIA Biotechnology Inc. MAIA

$76.6M

Frequently Asked Questions

What is JUPITER NEUROSCIENCES, INC.'s annual revenue?

JUPITER NEUROSCIENCES, INC. (JUNS) reported $22K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is JUPITER NEUROSCIENCES, INC. profitable?

No, JUPITER NEUROSCIENCES, INC. (JUNS) reported a net income of -$8.6M in fiscal year 2025, with a net profit margin of -39662.8%.

What is JUPITER NEUROSCIENCES, INC.'s gross margin?

JUPITER NEUROSCIENCES, INC. (JUNS) had a gross margin of 80.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is JUPITER NEUROSCIENCES, INC.'s operating margin?

JUPITER NEUROSCIENCES, INC. (JUNS) had an operating margin of -40873.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is JUPITER NEUROSCIENCES, INC.'s net profit margin?

JUPITER NEUROSCIENCES, INC. (JUNS) had a net profit margin of -39662.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is JUPITER NEUROSCIENCES, INC.'s operating cash flow?

JUPITER NEUROSCIENCES, INC. (JUNS) generated -$5.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are JUPITER NEUROSCIENCES, INC.'s total assets?

JUPITER NEUROSCIENCES, INC. (JUNS) had $5.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does JUPITER NEUROSCIENCES, INC. spend on research and development?

JUPITER NEUROSCIENCES, INC. (JUNS) invested $2.1M in research and development during fiscal year 2025.

How many shares does JUPITER NEUROSCIENCES, INC. have outstanding?

JUPITER NEUROSCIENCES, INC. (JUNS) had 34M shares outstanding as of fiscal year 2025.

What is JUPITER NEUROSCIENCES, INC.'s current ratio?

JUPITER NEUROSCIENCES, INC. (JUNS) had a current ratio of 0.65 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is JUPITER NEUROSCIENCES, INC.'s debt-to-equity ratio?

JUPITER NEUROSCIENCES, INC. (JUNS) had a debt-to-equity ratio of -4.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is JUPITER NEUROSCIENCES, INC.'s return on assets (ROA)?

JUPITER NEUROSCIENCES, INC. (JUNS) had a return on assets of -155.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is JUPITER NEUROSCIENCES, INC.'s cash runway?

Based on fiscal year 2025 data, JUPITER NEUROSCIENCES, INC. (JUNS) had $3.8M in cash against an annual operating cash burn of $5.4M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is JUPITER NEUROSCIENCES, INC.'s debt-to-equity ratio negative or unusual?

JUPITER NEUROSCIENCES, INC. (JUNS) has negative shareholder equity of -$1.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is JUPITER NEUROSCIENCES, INC.'s Piotroski F-Score?

JUPITER NEUROSCIENCES, INC. (JUNS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are JUPITER NEUROSCIENCES, INC.'s earnings high quality?

JUPITER NEUROSCIENCES, INC. (JUNS) has an earnings quality ratio of 0.63x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can JUPITER NEUROSCIENCES, INC. cover its interest payments?

JUPITER NEUROSCIENCES, INC. (JUNS) has an interest coverage ratio of -134.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is JUPITER NEUROSCIENCES, INC.?

JUPITER NEUROSCIENCES, INC. (JUNS) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.